Thyrocare Technologies Limited announced that its Board of Directors has approved significant amendments to its insider trading compliance framework during a meeting held on January 28, 2026.

Board Meeting Details

The company's Board of Directors convened on Wednesday, January 28, 2026, to consider and approve amendments to the Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, commonly referred to as the PIT Code.

Code of Conduct Framework

The amended code establishes comprehensive guidelines under SEBI's Prohibition of Insider Trading Regulations, 2015. The 37-page document outlines detailed procedures for preventing misuse of unpublished price sensitive information (UPSI) and establishes trading restrictions for designated persons.

Key components of the amended code include:

• Trading Window Restrictions: Closure from end of every quarter until 48 hours after financial results declaration
• Pre-clearance Requirements: Mandatory approval for all trades by designated persons during open trading windows
• Disclosure Obligations: Initial and continual disclosure requirements for securities transactions exceeding ₹10,00,000
• Structured Digital Database: Maintenance of records for persons with whom UPSI is shared

Compliance and Monitoring Mechanisms

The code designates the Company Secretary as the Compliance Officer, responsible for monitoring adherence to insider trading regulations. The framework includes specific provisions for trading plans, reporting requirements, and penalty structures for violations.

Regulatory Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The amended PIT Code has been made available on the company's investor website at https://investor.thyrocare.com/policies-codes/ .

This amendment reflects Thyrocare Technologies' commitment to maintaining robust corporate governance standards and ensuring compliance with evolving regulatory requirements in the Indian securities market.

Thyrocare Technologies Limited announced its quarterly financial results and key board decisions for the period ended December 31, 2025, following a board meeting held on January 28, 2026.

Financial Results Approval

The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The financial statements were accompanied by limited review reports issued by the company's statutory auditors, MSKA & Associates LLP.

Standalone Financial Performance

Nine Months Performance

For the nine months ended December 31, 2025, the company reported revenue from operations of ₹563.60 crores compared to ₹459.23 crores in the corresponding period of the previous year, representing a growth of 22.7%. Net profit for the nine-month period stood at ₹105.23 crores versus ₹73.96 crores in the previous year.

Consolidated Results

The consolidated financial results showed revenue from operations of ₹195.53 crores for Q3 FY26 compared to ₹165.92 crores in Q3 FY25. Consolidated net profit reached ₹28.05 crores against ₹18.95 crores in the corresponding quarter of the previous year.

Exceptional Items Impact

The company reported exceptional items of ₹5.97 crores in Q3 FY26, primarily due to incremental gratuity impact of ₹4.01 crores arising from changes in wage definitions under the New Labour Codes implemented from November 21, 2025. Additional exceptional items of ₹1.96 crores were related to non-recurring costs associated with capital restructuring.

Code of Conduct Amendment

The Board approved amendments to the "Code of Conduct to Regulate, Monitor, and Report Trading by Designated Persons and their Immediate Relatives." This code ensures compliance with SEBI's Prohibition of Insider Trading Regulations, 2015. The amended code includes updated definitions, trading restrictions, and disclosure requirements for designated persons and their immediate relatives.

Bonus Share Details

The company had previously completed a 2:1 bonus share issuance approved by shareholders through postal ballot on November 16, 2025. The Stakeholders Relationship Committee allotted 10,61,07,794 equity shares of ₹10 each as fully paid-up bonus shares on December 1, 2025, to eligible members whose names appeared in the register as of November 28, 2025.

Business Segments

The company operates through three primary segments:

The diagnostic testing services segment, which forms the core business, showed strong growth of 20.1% year-over-year. The segment contributed ₹36.82 crores in profit before tax for Q3 FY26.

Corporate Governance

The board meeting commenced at 3:30 PM and concluded at 4:05 PM on January 28, 2026. All disclosures have been made available on the company's website and will be submitted to BSE and NSE as per regulatory requirements.